You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 16, 2024

Claims for Patent: 9,931,402

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,931,402

Title:	Compositions for the treatment of solid tumors
Abstract:	The present invention relates to a pharmaceutical combination that comprises an IGF1R inhibitor and an mTOR inhibitor for the treatment of cancer in a subject; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of medicament for the treatment of cancer; a kit comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and a method of treating cancer in a subject, especially a human.
Inventor(s):	Hurwitz; Herbert I. (Durham, NC), Vlahovic; Gordana (Durham, NC)
Assignee:	Duke University (Durham, NC)
Application Number:	15/586,727
Patent Claims:	1. A pharmaceutical composition comprising an IGF1R inhibitor and an mTOR inhibitor in a pharmaceutically acceptable carrier, wherein the IGF1R inhibitor is ganitumab and the mTOR inhibitor is everolimus. 2. The composition of claim 1, wherein the composition comprises ganitumab is in an amount of about 0.05 mg to about 5 g. 3. The composition of claim 1, wherein the composition comprises ganitumab is in an amount of about 0.5 mg to about 5 g. 4. The composition of claim 1, wherein the composition comprises ganitumab is in an amount of about 1 mg to about 2 g. 5. The composition of claim 1, wherein the composition comprises everolimus in an amount of about 0.1 mg to about 10 mg. 6. The composition of claim 1, wherein the composition comprises everolimus in an amount of about 2 mg to about 8 mg. 7. The composition of claim 1, wherein the composition comprises everolimus in an amount of about 5 mg. 8. A kit comprising an IGF1R inhibitor and an mTOR inhibitor, wherein the IGF1R inhibitor is ganitumab and the mTOR inhibitor is everolimus, and printed instructions directing the use of a combined treatment of ganitumab and everolimus for treating cancer in a subject. 9. The kit of claim 8, wherein the ganitumab and the everolimus are in separate containers. 10. The kit of claim 9, wherein the ganitumab and the everolimus are in separate containers. 11. The kit of claim 8, wherein the ganitumab and the everolimus are in a unit dosage form. 12. The kit of claim 11, herein the ganitumab and the everolimus are in the same containers. 13. The kit of claim 8, further comprising a sterile diluent.

Details for Patent 9,931,402

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006	⤷ Try a Trial	2031-11-11
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.